Department of Urology, The Third Xiangya Hospital, Central South
University, Changsha, Hunan 410013, China
Objectives: To compare the safety and efficacy of transurethral
plasmakinetic prostate resection (PKPR) and transvesical
prostectomy (TVP) for the treatment of benign prostatic
hyperplasia (BPH) with a prostate volume of 100-149 mL.
Methods: Ninety-nine BPH patients with a prostatic volume of
100-149 mL were randomized into the PKRP and TVP groups.
The relevant clinical data were reviewed preoperatively. Patients
had follow-up appointments at one, three, six and 12 months
postoperatively. The assessment indicators included the
international prostate symptom score (IPSS), the quality of life
score (QoL), the maximum urinary flow rate (Qmax) and the
post-void residual urine volume (PVR). Adverse events were
Results: A total of 96 patients completed the 12-month followup.
The operative time was longer, but intraoperative blood loss
was lower in the PKRP group. Despite a higher blood transfusion
rate, there was an obvious advantage in gland removal rate in
the TVP group. The duration of postoperative catheterization,
bladder irrigation and hospital stay was significantly shorter
in the PKRP group. Assessment indicators were significantly
improved in both groups at one month postoperatively. The
improvement in lower urinary tract symptoms was maintained
throughout the 12 months after surgery. There were no
significant differences in IPSS, QoL, Qmax and PVR between the
two groups. The PKRP group had a higher incidence of urethral
stricture than the TVP group.
Conclusions: PKRP is a safe and effective treatment method
and can achieve the effects of traditional open surgery for the
treatment of BPH with a prostate volume of 100-149 mL.
Benign prostatic hyperplasia; large volume prostate;
transurethral plasma kinetic prostate resection; transbladder
vaporization of prostate